As recently as December 10, 2025, Rezolute was a Wall Street darling. Eight analysts rated the stock a Buy, with price targets as high as $17. Its lead drug ersodetug, a monoclonal antibody, had earned two FDA Breakthrough Therapy Designations and the agency had signaled that its Phase 3 trial could support a BLA filing.…
XOMA acquires Ixinity’s commercial payment and milestone rights in $9.6M
Biotech royalty aggregator XOMA (Nasdaq:XOMA) has acquired the commercial payment and part of the milestone rights to Ixinity (trenonacog alfa), a hemophilia B therapy originally from Aptevo Therapeutics (Nasdaq:APVO). The aggregator expects the move to bolster its royalty and milestone portfolio, potentially providing consistent cash flow and ramping up its royalty aggregation strategy. The acquired…